1. Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial. Issue 3 (March 2023) Authors: Manno, Daniela; Bangura, Agnes; Baiden, Frank; Kamara, Abu Bakarr; Ayieko, Philip; Kallon, Joseph; Foster, Julie; Conteh, Musa; Connor, Nicholas Edward; Koroma, Bockarie; Njie, Yusupha; Borboh, Paul; Keshinro, Babajide; Lawal, Bolarinde Joseph; Kroma, Mattu Tehtor; Otieno, Godfrey Tuda; Deen, Abd... Journal: Lancet infectious diseases Issue: Volume 23:Issue 3(2023) Page Start: 352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗